Policy and advocacy content. This article presents evidence-based policy analysis on public health funding priorities. It does not constitute medical advice. Readers seeking personal health guidance should consult a qualified healthcare professional.
Chronic Disease Prevention Funding in Australia: The Return on Investment Case
Australia spends approximately 1.5% to 2% of its total health expenditure on prevention. That figure, drawn from the Australian Institute of Health and Welfare's (AIHW) Health Expenditure Australia series, is not a rounding error — it is the structural baseline of a health system that, for decades, has made a rational-sounding but ultimately costly choice: to treat disease rather than prevent it. The consequences of that choice are now visible in every direction. Chronic diseases — cardiovascular disease, type 2 diabetes, cancer, chronic obstructive pulmonary disease (COPD), and mental health conditions — account for over 70% of Australia's disease burden and a corresponding share of health system expenditure. The Productivity Commission has estimated the total economic cost of preventable chronic disease at approximately $27 billion annually in lost productivity alone, before accounting for health system treatment costs.
The central claim of this analysis is straightforward: Australia's prevention spending profile is an investment failure with documented returns, not an unaffordable aspiration. The evidence base for prevention return on investment (ROI) is substantial, the international comparators are instructive, and the policy mechanisms to shift the system upstream are well understood. What has been missing is the political will to treat prevention as a capital investment rather than a discretionary line item.
The Prevention Paradox
The term "prevention paradox" in public health typically describes the epidemiological observation that large benefits at the population level often come from interventions that offer individually small risk reductions across many people. In the Australian health funding context, the paradox takes a different form: the activities with the highest long-run return on investment receive the smallest share of public health funding.
The AIHW Health Expenditure Australia 2022–23 report documents total health expenditure of approximately $245 billion. Of this, recurrent expenditure on public health activities — the category that captures health promotion, disease prevention, population health screening, and environmental health — was approximately $3.7 billion, or roughly 1.5% of the total. Hospital services, by contrast, absorbed approximately 40% of health expenditure, and a substantial portion of that hospital demand is driven by conditions with well-established preventable components: ischaemic heart disease, stroke, type 2 diabetes complications, preventable cancer presentations, and alcohol-related injury.
This is not primarily a failure of knowledge. Australia has produced high-quality prevention evidence through bodies including the National Health and Medical Research Council (NHMRC), the Doherty Institute, and successive National Preventive Health Strategies. The 2021 National Preventive Health Strategy set an explicit target of increasing prevention expenditure to 5% of health spending by 2030 — the OECD average. Four years on, there is limited public evidence that expenditure has shifted materially toward that target.
The OECD Comparison
Australia's prevention spending profile sits consistently below the OECD average when measured as a proportion of total health expenditure. OECD Health at a Glance data (2023 edition) places the OECD average for public health and prevention spending at approximately 3% of health expenditure. Several high-performing health systems allocate considerably more.
Nordic countries. Finland, Sweden, and Denmark allocate between 3.5% and 5% of health expenditure to prevention and public health activities. These countries have not simply spent more on prevention in the abstract — they have embedded prevention into primary care architecture. General practice contracts in the Nordic systems include explicit preventive care obligations: cardiovascular risk screening, diabetes prevention counselling, childhood development monitoring, and smoking cessation support are funded components of the primary care service specification, not optional extras constrained by appointment time economics.
Canada. Canada's public health system, anchored by the Public Health Agency of Canada and its provincial equivalents, allocates approximately 4% of health expenditure to prevention and population health. Canada's experience with the Diabetes Prevention Program — delivered through provincial primary care networks — is directly relevant to the Australian context and is examined in detail below.
New Zealand. New Zealand allocates approximately 3.5% of health spending to prevention and public health via the Public Health Agency established within Health New Zealand in 2022. The Māori Health Authority framework has explicitly linked prevention investment to equity outcomes, recognising that chronic disease burden falls disproportionately on populations with lower socioeconomic status and restricted access to primary care — a pattern directly parallel to Australia's Indigenous health gap.
What higher-spending prevention countries do differently is not mysterious. They fund primary care prevention explicitly through capitation contracts rather than fee-for-service episodic billing, invest in community health workers and health promotion outreach, subsidise healthy food access and active transport infrastructure, and treat health literacy as a component of the national education system rather than a peripheral activity.
The Return on Investment Evidence
The economic case for prevention investment is not speculative. It has been quantified across multiple domains and methodological frameworks.
The World Health Organization's analysis of prevention investment returns — most recently synthesised in the Best Buys framework for noncommunicable disease — estimates that every dollar invested in proven prevention interventions returns approximately $14 in reduced treatment costs and productivity gains. This 14:1 return is a weighted average across tobacco control, harmful alcohol use reduction, physical inactivity interventions, and unhealthy diet programs — the four behavioural risk factors that collectively drive the majority of chronic disease incidence.
Tobacco control. Australia's tobacco control program — combining excise taxation, plain packaging legislation, advertising restrictions, and cessation support — is widely cited as among the most cost-effective public health investments in the country's history. Research by Collins and colleagues (2015), modelling the long-run health system savings from sustained reductions in smoking prevalence, estimated net present value returns in excess of $10 for every $1 invested in the comprehensive tobacco control package. Adult smoking prevalence in Australia has fallen from approximately 24% in the mid-1990s to approximately 11% in 2022–23 (AIHW National Drug Strategy Household Survey). The avoided cardiovascular disease, lung cancer, COPD, and stroke hospitalisations attributable to this decline represent billions of dollars in avoided health system costs annually — costs that were never incurred because a prevention investment worked.
Obesity prevention. Obesity prevention programs deliver positive ROI across multiple evaluation frameworks. NHMRC-funded modelling of community-based obesity prevention programs — targeting physical activity and dietary change in childhood and adolescent populations — consistently finds benefit-cost ratios between 5:1 and 12:1, primarily driven by avoided type 2 diabetes, cardiovascular disease, and musculoskeletal conditions in adulthood. The ACE-Prevention (Assessing Cost-Effectiveness in Prevention) project, one of the most comprehensive economic assessments of health interventions conducted in Australia, ranked obesity prevention measures including taxation on sugar-sweetened beverages, front-of-pack food labelling reform, and active transport infrastructure among the most cost-effective interventions available to Australian policymakers.
Productivity costs of inaction. The Productivity Commission's Productivity Inquiry: Australia's Productivity Performance (2023) and associated health system analysis placed the aggregate productivity cost of preventable chronic disease at approximately $27 billion annually. This figure captures absenteeism, presenteeism (reduced productivity while at work due to chronic health conditions), early exit from the workforce, and carer burden. It does not include the direct health system treatment cost, which the AIHW estimates in the tens of billions per year for chronic disease management and its acute complications.
The Treatment-Oriented Incentive Structure
Understanding why Australia underinvests in prevention requires examining the incentive architecture of the health system, not simply the preferences of policymakers. The current structure systematically rewards treatment over prevention at every level.
Medicare's fee-for-service model. The Medicare Benefits Schedule (MBS) is structured around episodic treatment events. GP consultations are billed per attendance, with remuneration tied to time and complexity of the individual encounter. There is no MBS structure that pays a GP for preventing a patient from needing to attend. Health Assessments (items 701–715) and Chronic Disease Management plans (items 721–779) provide some financial support for preventive activity, but the per-consultation economics create a ceiling: a GP with a 15-minute appointment schedule and a practice overhead of $70 to $90 per slot cannot devote consultation time to lifestyle counselling, dietary assessment, or smoking cessation support at current rebate levels without financial loss. Prevention, under the current MBS, is what GPs do after they have covered their costs on other items — not a funded service in its own right.
Activity-based hospital funding. Public hospital funding in Australia is primarily delivered through National Health Reform Agreement activity-based funding (ABF) arrangements, under which hospitals receive payment per episode of care (weighted by the National Efficient Price). This model creates a direct financial incentive for hospitals to perform procedures and manage acute presentations. A hospital that reduces preventable admissions through better community chronic disease management receives less funding, not more. The incentive structure is precisely inverted relative to the public health objective.
Specialist remuneration relativities. The earnings gap between general practice and hospital-based specialties — driven partly by MBS rebate structures and partly by private billing practices — systematically draws medical graduates toward procedural and specialist careers and away from general practice. Prevention and population health are primarily delivered through primary care. A system that undervalues primary care relative to acute care is also, structurally, a system that undervalues prevention.
Type 2 Diabetes: A Case Study in Prevention Underfunding
Type 2 diabetes (T2D) is the most comprehensively studied chronic disease from a prevention economics perspective, and the Australian data illustrate the prevention funding failure with particular clarity.
Approximately 1.3 million Australians are currently diagnosed with type 2 diabetes, according to Diabetes Australia and the AIHW Diabetes: Australian Facts series. A further estimated 2 million Australians have impaired fasting glucose or impaired glucose tolerance — the prediabetes states that substantially elevate T2D risk — the majority of whom are unaware of their status. At current incidence trajectories, Diabetes Australia projects the diagnosed T2D population will exceed 1.7 million by 2030.
The direct health system cost of T2D in Australia — including GP management, pharmaceutical costs (insulin, metformin, SGLT-2 inhibitors, GLP-1 receptor agonists), diabetes nurse educator and dietitian services, and management of complications including cardiovascular disease, chronic kidney disease, retinopathy, and lower limb amputation — is estimated at over $3 billion annually. The complication burden is concentrated in the later disease stages, meaning that delaying or preventing T2D onset translates directly into avoided high-cost interventions.
The international evidence on diabetes prevention is unambiguous. The Diabetes Prevention Program (DPP) trial, conducted in the United States and replicated across multiple settings, demonstrated that an intensive lifestyle intervention — targeting modest weight loss (5–7% of body weight), physical activity (150 minutes per week), and dietary change — reduced T2D incidence in high-risk individuals by 58% over three years. Metformin reduced incidence by 31%. The lifestyle intervention outperformed medication, was durable over long follow-up, and was most cost-effective when delivered to younger high-risk individuals. Cost-effectiveness analyses of the DPP consistently find incremental cost-effectiveness ratios well within accepted thresholds, and some analyses find net cost savings over ten-year horizons when complication costs are included.
Finland's national success. Finland provides the most compelling national-scale demonstration of diabetes prevention investment. Following the original Finnish Diabetes Prevention Study, Finland established a national diabetes prevention program (FIN-D2D) that translated the trial's lifestyle intervention into a primary care delivery model. Over a decade of implementation, Finland significantly reduced T2D incidence in the target population and demonstrated that community-delivered prevention programs — run through primary care nurses, physiotherapists, and health coaches — can achieve clinically meaningful outcomes at scale. Finland now has one of the lowest T2D prevalence rates in the European Union.
Australia's prevention gap. Australia's National Diabetes Services Scheme (NDSS) provides subsidised supplies and education for diagnosed T2D patients but does not currently fund a national diabetes prevention program at meaningful scale. The Life! programme in Victoria is a state-level exception — a group-based lifestyle modification program for high-risk individuals that has demonstrated effectiveness in the Australian context — but it reaches a small fraction of the estimated 2 million Australians at prediabetes risk. The gap between the evidence base for prevention and the funded delivery infrastructure is not a knowledge problem. It is a funding allocation problem.
Policy Reforms: What Would It Actually Take?
The Coalition for Better Health's assessment is that shifting Australia's health system meaningfully upstream requires a coordinated package of reforms across funding levels, incentive structures, and governance architecture.
Increase prevention expenditure to 5% of health expenditure. The National Preventive Health Strategy's own target of 5% by 2030 represents the OECD average — not an ambitious aspiration but a minimum parity benchmark. Reaching this target would require an additional $3 billion to $4 billion annually in prevention-specific expenditure. Set against the $27 billion annual productivity cost of preventable chronic disease and the multi-billion treatment cost of conditions like T2D, cardiovascular disease, and preventable cancer, this is a high-return capital allocation.
Reform Medicare to fund prevention explicitly. The MBS must be restructured to fund preventive care as a service category in its own right. This means adequately rebated annual cardiovascular risk assessments for adults over 45 (and over 35 for First Nations people and those with specific risk factors); funded lifestyle prescription consultations with allied health professionals (dietitians, exercise physiologists, health coaches); and capitation or blended payment arrangements for general practices that demonstrate chronic disease prevention outcomes. The Health Care Homes model, piloted from 2017 to 2022, demonstrated both the potential and the implementation challenges of moving toward capitation-blended primary care funding — lessons that should inform rather than preclude further reform.
Transition hospital funding toward outcomes-based payments. Activity-based funding should incorporate a prevention and avoidable admission component: hospitals and local health networks should receive funding credits for reduced preventable hospitalisation rates in their catchment populations. This requires investment in linked data infrastructure so that preventable admission rates can be attributed to geographic catchments and primary care providers with sufficient reliability to form the basis of funding adjustments.
Establish an adequately funded Australian Health Promotion Authority. The Australian National Preventive Health Agency was abolished in 2014. Its successor functions were absorbed into the Department of Health without dedicated statutory authority or ring-fenced funding. A national prevention body with independent statutory standing, dedicated capital, a mandate to commission and evaluate prevention programs, and authority to advise the Commonwealth on preventive health investment priorities is a governance prerequisite for systematic prevention scale-up.
Food labelling and environment reform. Australia's Health Star Rating system is voluntary. The evidence from mandatory traffic light labelling systems in the UK and health star rating evaluations in Australia consistently shows that mandatory front-of-pack nutrition labelling influences purchasing behaviour, particularly for lower-health-literacy consumers who are also at higher chronic disease risk. A mandatory Health Star Rating system, combined with a levy on high-sugar discretionary foods, would generate both fiscal revenue for prevention programs and a direct dietary behaviour signal. Companion investment in active transport infrastructure — cycling lanes, pedestrian connectivity, public open space — creates the built environment conditions in which physical activity is the default rather than a deliberate choice.
Health literacy as a national curriculum priority. Population health literacy — the capacity to understand and act on health information — is one of the strongest predictors of chronic disease prevention behaviour. Australia's health literacy levels, measured against the international Health Literacy Survey instruments, show a substantial proportion of the adult population operating below the level required to navigate the health system effectively. Embedding health literacy within the national school curriculum and funding community health literacy programs through Primary Health Networks would address the knowledge and agency gap that undermines individual prevention behaviour even when the structural conditions support it.
The GP workforce and primary care access crises explored in our GP workforce shortage analysis and bulk billing policy analysis are downstream symptoms of a health system that has concentrated resources in acute treatment. Prevention investment is not a separate policy agenda from primary care reform — it is its upstream precondition. And tackling chronic disease at its origins is also the most credible long-run strategy for addressing childhood obesity, where the trajectory of adult chronic disease burden is set earliest and preventive returns are highest.
The Fiscal Case for Political Will
The objection to prevention investment that recurs most reliably in budget processes is timing: prevention returns are long-run, while budget constraints are annual. A diabetes prevention program launched this year will reduce hospitalisation costs most visibly in ten to fifteen years. Treasury discount rates and political cycles both work against investments with deferred payoffs.
This objection, while real, does not survive scrutiny for three reasons. First, some prevention investments — tobacco cessation support, hypertension screening and treatment, high-risk pregnancy support — return measurable cost savings within three to five years, well within a single term of government. Second, the opportunity cost of inaction is not deferred — Australia is already spending $27 billion annually in preventable productivity losses and billions more in avoidable treatment costs. The question is not whether prevention costs money but whether continued inaction does. Third, intergenerational equity arguments — the obligation to avoid locking in a higher chronic disease burden for future generations — are legitimate public finance considerations that budget frameworks are capable of accommodating when political will exists, as infrastructure investment accounting demonstrates.
Australia has the evidence, the international comparators, the policy instruments, and the economic case for a fundamental shift in how its health system allocates resources. What has been missing is a sustained political commitment to treat prevention as the high-return investment the data show it to be, rather than the soft-target expenditure line it has historically functioned as.
This analysis represents the Coalition for Better Health's policy advocacy position, based on publicly available data from the AIHW, Productivity Commission, OECD, WHO, and peer-reviewed prevention economics literature.